Please assess the completion status of the following clinical trial:

Trial Title: Changes of Inflammatory Cytokines in the Tears of Moderate and Severe MGD Treated With Topical Loteprednol Etabonate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~(1) stage 3 or 4 meibomian gland dysfunction~Exclusion Criteria:~1. history of previous ocular or intraocular surgery~2. ocular infection, non dry eye ocular inflammation, ocular allergy, autoimmune disease,~3. history of intolerance or hypersensitivity to any component of the study medications,~4. wearing contact lenses during the study period, presence of current punctal occlusion,~5. pregnancy, lactating women, and children.~6. Additionally, patients were excluded if they were using any topical ocular or systemic medication that could be used for the treatment MGD or dry eye, including topical or oral antibiotics, topical cyclosporine A, topical or oral steroids, topical non-steroidal anti-inflammatory drugs, topical ocular allergy medications or artificial tears

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lotemax with warm compress group (Type: EXPERIMENTAL): topical loteprednol etabonate (lotemax 0.5%) qid and warm compress \& ocular massage (a minimum of four times, once or twice a daily) for 2months
- warm compress only group (Type: ACTIVE_COMPARATOR): warm compress only group

Based on this trial design, predict the completion outcome and termination type (if applicable).